NovaBridge Biosciences (NBP) CFO reports 2025 employee option stake

Rhea-AI Filing Summary

NovaBridge Biosciences disclosed initial insider holdings for its Chief Financial Officer, Lei Ming Kyler, through a 2025 Employee Share Option award. The option covers 996,775 underlying securities at an exercise price of 4.25 per ADS and expires on October 16, 2035.

According to the footnotes, the option was granted on October 16, 2025 and vests over five years, with 40% vesting on the second anniversary of the grant date and the remainder vesting in equal portions on each following anniversary. The filing reflects existing option holdings rather than a new market purchase or sale.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lei Ming Kyler

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2025 Employee Share Option (right to buy)	(3)	10/16/2035	Ordinary Shares(1)	996,775(2)	$4.25(2)	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Number of underlying securities and exercise price expressed in terms of ADSs.

3. The option was granted on October 16, 2025. The option vests and becomes exercisable over five years, with four-tenths vesting on the second anniversary of the grant date and the balance vesting ratably on each subsequent anniversary of the grant date.

Remarks:

Exhibit List: Ex. 24.1 - Power of Attorney

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does NovaBridge Biosciences (NBP) Form 3 filing show for Lei Ming Kyler?

The Form 3 shows that CFO Lei Ming Kyler holds a 2025 Employee Share Option covering 996,775 underlying securities, with an exercise price of 4.25 per ADS and expiration on October 16, 2035, establishing her initial reported derivative ownership position.

What are the key terms of Lei Ming Kyler’s 2025 Employee Share Option at NovaBridge Biosciences (NBP)?

The 2025 Employee Share Option has an exercise price of 4.25 per ADS, covers 996,775 underlying securities and expires on October 16, 2035. It was granted on October 16, 2025 under a long-term vesting schedule described in the filing’s footnotes.

How does the 2025 Employee Share Option for NovaBridge Biosciences (NBP) CFO vest over time?

The option vests over five years. Forty percent vests on the second anniversary of the October 16, 2025 grant date. The remaining balance then vests in equal installments on each subsequent anniversary, aligning the CFO’s incentives with longer-term company performance.

How are NovaBridge Biosciences (NBP) ADSs related to its ordinary shares in this Form 3?

The filing explains that the company’s ordinary shares may be represented by American Depositary Shares. Each 10 ADSs represent 23 ordinary shares. It also notes that both the option’s underlying securities and exercise price are expressed in terms of ADSs for reporting purposes.

Does the NovaBridge Biosciences (NBP) Form 3 reflect any insider share purchases or sales?

The Form 3 primarily records existing derivative holdings, specifically the 2025 Employee Share Option, rather than open-market purchases or sales. Transaction summaries show no buy or sell activity, indicating this filing serves as an initial ownership statement for the CFO’s option position.